The price of Doximity Inc (NYSE: DOCS) closed at $26.42 in the last session, up 2.21% from day before closing price of $25.85. In other words, the price has increased by $+0.57 from its previous closing price. On the day, 1053677 shares were traded.
Ratios:
We take a closer look at DOCS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.68. For the most recent quarter (mrq), Quick Ratio is recorded 7.97 and its Current Ratio is at 7.97. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Market Perform rating and assigned the stock a target price of $32.
On January 03, 2024, Barclays started tracking the stock assigning a Equal Weight rating and target price of $31.
BofA Securities Upgraded its Underperform to Neutral on January 02, 2024, whereas the target price for the stock was revised from $21 to $29.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Wampler Kira Scherer sold 2,500 shares for $26.97 per share. The transaction valued at 67,425 led to the insider holds 10,258 shares of the business.
Wampler Kira Scherer sold 2,500 shares of DOCS for $69,700 on Mar 01 ’24. The Director now owns 10,258 shares after completing the transaction at $27.88 per share. On Feb 16 ’24, another insider, Overpeck Craig, who serves as the insider of the company, sold 1,500 shares for $30.02 each. As a result, the insider received 45,030 and left with 112,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DOCS now has a Market Capitalization of 4.93B and an Enterprise Value of 4.23B. As of this moment, Doximity’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.81, and their Forward P/E ratio for the next fiscal year is 27.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.77. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.52 while its Price-to-Book (P/B) ratio in mrq is 5.69. Its current Enterprise Value per Revenue stands at 9.04 whereas that against EBITDA is 24.44.
Stock Price History:
Over the past 52 weeks, DOCS has reached a high of $37.10, while it has fallen to a 52-week low of $19.71. The 50-Day Moving Average of the stock is 27.78, while the 200-Day Moving Average is calculated to be 26.57.
Shares Statistics:
According to the various share statistics, DOCS traded on average about 1.78M shares per day over the past 3-months and 1.79M shares per day over the past 10 days. A total of 120.68M shares are outstanding, with a floating share count of 117.86M. Insiders hold about 36.83% of the company’s shares, while institutions hold 49.66% stake in the company. Shares short for DOCS as of Mar 15, 2024 were 7.65M with a Short Ratio of 5.13, compared to 7.98M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.10% and a Short% of Float of 7.28%.
Earnings Estimates
The company has 14 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.2 for the current quarter, with a high estimate of $0.22 and a low estimate of $0.14, while EPS last year was $0.2. The consensus estimate for the next quarter is $0.21, with high estimates of $0.25 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.92 and $0.87 for the fiscal current year, implying an average EPS of $0.9. EPS for the following year is $0.95, with 14 analysts recommending between $1.03 and $0.87.
Revenue Estimates
According to 14 analysts, the current quarter’s revenue is expected to be $116.49M. It ranges from a high estimate of $116.76M to a low estimate of $116M. As of the current estimate, Doximity Inc’s year-ago sales were $110.97M, an estimated increase of 5.00% from the year-ago figure.
A total of 17 analysts have provided revenue estimates for DOCS’s current fiscal year. The highest revenue estimate was $474.12M, while the lowest revenue estimate was $473M, resulting in an average revenue estimate of $473.84M. In the same quarter a year ago, actual revenue was $419.05M, up 13.10% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $520.99M in the next fiscal year. The high estimate is $526.06M and the low estimate is $514.37M. The average revenue growth estimate for next year is up 10.00% from the average revenue estimate for this year.
